Preventive care and screenings

Preventive care is the part of health where the recommendations are written down, graded and dated, and where most of the confusion comes from reading a discussion paragraph as if it were a rule. This pillar collects the guides that separate the two: what the US Preventive Services Task Force, the CDC's immunization schedule and the specialty societies actually recommend, at what age, how often, and with what grade. The decade hubs hold the full screening ledgers for each age; the guides here explain the rows people most often misread.

The PSA chart that circulates online, one cutoff per decade, is not a guideline. The National Cancer Institute states that there is no single threshold separating a normal from an abnormal PSA result. The familiar 4 ng/mL is historical, and the decade cutoffs that circulate (2.5, 3.5, 4.5 and 6.5 ng/mL) sit in the AUA guideline's discussion text citing work from 1993; they are not a numbered recommendation and carry no evidence grade. What the AUA/SUO guideline does set by age, with grades, is when to start: a baseline PSA at 45 to 50, from 40 to 45 at higher risk, and screening every 2 to 4 years from 50 to 69. The USPSTF, whose 2018 statement is under update, grades screening at 55 to 69 a C, an individual decision, and recommends against it at 70 and over, a D. Normal PSA levels by age lays this out against the AUA/SUO guideline and the USPSTF statement, and the PSA reference ledger prints the rows with their sources.

Adult vaccination in the US is set out in the CDC's adult immunization schedule, which is organized by age and risk rather than by decade of life. Vaccines recommended after 50, by decade restates it in the order a reader ages through it: an annual influenza vaccine and a Tdap then a Td or Tdap booster every 10 years in every decade; at 50, two doses of recombinant zoster vaccine (Shingrix) 2 to 6 months apart regardless of prior shingles or chickenpox, and pneumococcal vaccination with one dose of PCV15, PCV20 or PCV21 (a PCV15 start is followed by PPSV23); RSV as a routine single dose at 75 or older and risk-based from 50 to 74. The guide is dated to the schedule's July 2, 2025 version, which the CDC amended on April 27, 2026 to add the RSV recommendation for adults 50 to 74 and still publishes as current as of September 2026.

Three habits keep a preventive-care decision honest. First, read the grade. The USPSTF's own definitions: A and B mean it recommends the service, C means offer it selectively because the net benefit is small, D means it recommends against, and I means the evidence is insufficient to say. Second, read the population: a row that says "adults 50 to 69" says nothing about a 45-year-old, and a start age can move earlier on personal or family history. Third, read the date: the USPSTF's 2018 prostate statement is listed as under update, and the CDC normally revises its schedule each year, so a page that does not carry a date is not a source. The screenings-by-age tool applies those habits for you: enter an age and it returns the rows for that decade with the recommending body, its grade and the date on each.